

AMENDMENTS TO THE CLAIMS

1-11. (canceled)

12. (previously presented): An isolated recombinant protein comprising the amino acid sequence of SEQ ID NO:2.

13. (canceled)

14. (previously presented): An isolated recombinant protein that has an amino acid sequence encoded by a polynucleotide selected from the group consisting of:

(a) a polynucleotide having the sequence as shown in SEQ ID NO:1, wherein T can also be U;

(b) a polynucleotide having the sequence as shown in SEQ ID NO:1, from nucleotide residue number 163 through nucleotide residue number 1674, wherein T can also be U;

(c) a polynucleotide encoding a protein whose sequence is encoded by the cDNAs contained in the plasmids designated p84P2A9-1 deposited with American Type Culture Collection as Accession No. PTA-1151;

(d) a polynucleotide encoding a protein having the amino acid sequence shown in SEQ ID NO:2; and

(e) a polynucleotide that is fully complementary to a polynucleotide of any one of (a)-(d).

15. (currently amended): The isolated recombinant protein of claim 14, wherein the recombinant protein is encoded by a polynucleotide comprising the sequence as shown in SEQ ID NO:1, from nucleotide residue number 720 through nucleotide residue number 1392. ~~selected from the group consisting of:~~

~~(a) a polynucleotide having the sequence as shown in SEQ ID NO:1, from nucleotide residue number 720 through nucleotide residue number 1392; or~~

~~(b) — a polynucleotide that selectively hybridizes under stringent conditions to the polynucleotide of (a).~~

16-38. (canceled)

39. (previously presented): A pharmaceutical composition comprising a recombinant protein, wherein the protein comprises the amino acid sequence of SEQ ID NO: 2, and a physiologically acceptable carrier.

40-48. (canceled)